Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment
By
211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
By
Filter posts by category
Radiotheranostics
Radiotheranostics is an advanced approach in modern oncology that combines diagnostic imaging and targeted radionuclide therapy within a unified strategy. It uses radiolabelled compounds that bind selectively to tumour-associated targets, allowing clinicians to first visualise disease distribution and then deliver therapeutic radiation to the same molecular sites. This integrated model supports personalised treatment planning by confirming adequate tumour uptake before therapy. Radiotheranostics has shown particular promise in prostate and neuroendocrine cancers, improving precision while limiting exposure to healthy tissue. Linking diagnosis directly with treatment enables real-time assessment of response and adaptive care. Ongoing advances in molecular targeting continue to expand its role in precision cancer medicine.
By
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment
By
Astatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 81C6-mAb: A Breakthrough in Brain Tumour Treatment with Alpha Radiation
By
211At-81C6-mAb, targeting tenascin in brain tumours, shows extended survival but needs further funding for development.
Exploring Actinium-225 RYZ101: A Promising Alpha-Labelled Analogue in Neuroendocrine Tumour Treatment
By
225Ac-RYZ101 offers promising GEP-NET treatment, targeting tumours with alpha particles via somatostatin receptor-specific edotreotate.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment
By
225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment
By
225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 MTI-201: A Promising New Agent in Uveal Melanoma Treatment
By
225Ac-MTI-201, targeting MC1R, offers groundbreaking, targeted treatment for uveal melanoma with minimal side effects.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment
By
225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 FPI-2265: A Promising Alpha Emitter for Metastatic Castration-Resistant Prostate Cancer Treatment
By
225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
Pioneering Targeted Alpha Therapy: Actinium-225 FPI-2068 and Indium-111 FPI-2107 in Solid Tumours
By
225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
Actinium-225 FPI-2059: Targeted Alpha Therapy in Oncology through NTSR1 Targeting
By
225Ac-FPI-2059 targets NTSR1 in cancer cells, offering a novel approach in pancreatic cancer treatment.
Actinium-225 FPI-1434 to Target Solid Tumours
By
225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
Actinium-225 DOTAZOL Alpharadiotherapy in Bone Diseases with a Focus on Prostate Cancer Treatment
By
225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
Actinium-225 DOTATOC: Transforming GEP-NET Treatment with Targeted Alpha Therapy in Refractory Cases
By
225Ac-DOTATOC advances GEP-NET treatment, offering targeted, effective therapy for patients resistant to traditional methods.
Actinium-225 DOTA-YS5: A Novel CD46-Targeted Radiopharmaceutical for Prostate Cancer Therapy
By
225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
Exploring the Potential of Actinium-225 DOTA-SP in Targeted Alpha Therapy for Cancer Treatment
By
225Ac-DOTA-SP, a breakthrough in targeted alpha therapy, offers precise cancer treatment with minimal side effects, revolutionising oncological approaches.
Personalised Theranostics for Cancer: A New Era in Precision Medicine
By
Theranostics is a cutting-edge approach that integrates diagnosis and therapy, enabling personalised and precise disease management.
Targeted radionuclide therapy (TAT) towards precision cancer treatment
By
Targeted radionuclide therapy was first used to treat cancer for an ‘over-active’ thyroid using radioactive iodine-131 seeds.
Radiolabelled Theranostic Agents for Targeted Cancer Diagnosis and Treatment
By
The nuclear medicine imaging approach is to use theranostics for example Zevalin to establish tools for specific molecular targeting.